Michael Overholtzer
Overview
Explore the profile of Michael Overholtzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
15196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gadal S, Boyer J, Roy S, Outmezguine N, Sharma M, Li H, et al.
Cancer Res
. 2025 Feb;
PMID: 39992718
BRAFV600E mutations occur in 46% of melanomas and drive high levels of ERK activity and ERK-dependent proliferation. However, BRAFV600E is insufficient to drive melanoma in genetically engineered mouse models, and...
2.
Conradt B, Miao E, Yuan J, Kanneganti T, Stockwell B, Tsvetkov P, et al.
Dev Cell
. 2024 Oct;
59(19):2519-2522.
PMID: 39378837
Various types of cell death program are needed for cells to respond to changes in physiological conditions. In this collection of Voices, we asked scientists to tell the story behind...
3.
Davidson A, Heron R, Das J, Overholtzer M, Wood W
Nat Cell Biol
. 2024 Jun;
26(9):1535-1544.
PMID: 38918597
Ferroptosis is a distinct form of necrotic cell death caused by overwhelming lipid peroxidation, and emerging evidence indicates a major contribution to organ damage in multiple pathologies. However, ferroptosis has...
4.
Keshari K, Heller D, Boltyanskiy R, Hricak H, Magaldi T, Overholtzer M
Cancer Cell
. 2024 Jun;
42(7):1138-1141.
PMID: 38848719
While cancer research and care have benefited from revolutionary advances in the ability to manipulate and study living systems, the field is limited by a lack of synergy to leverage...
5.
Gadal S, Boyer J, Roy S, Outmezguine N, Sharma M, Li H, et al.
bioRxiv
. 2024 Apr;
PMID: 38659913
mutation occurs in 46% of melanomas and drives high levels of ERK activity and ERK-dependent proliferation. However, is insufficient to drive melanoma in GEMM models, and 82% of human benign...
6.
Kim S, Lee D, Kim S, Overholtzer M
Exp Mol Med
. 2024 Apr;
56(4):870-876.
PMID: 38565900
Cell death pathways play critical roles in organism development and homeostasis as well as in the pathogenesis of various diseases. While studies over the last decade have elucidated numerous different...
7.
Klein A, Petruzzi K, Lee C, Overholtzer M
Mol Biol Cell
. 2024 Mar;
35(5):ar70.
PMID: 38536415
Lysosome turnover and biogenesis are induced in response to treatment of cells with agents that cause membrane rupture, but whether other stress conditions engage similar homeostatic mechanisms is not well...
8.
Trzeciak A, Rojas W, Liu Z, Krebs A, Wang Z, Saavedra P, et al.
bioRxiv
. 2023 Jun;
PMID: 37383948
Highlights: Myeloid-specific WNK1 loss causes failed macrophage development and premature deathM-CSF-stimulated myeloid progenitors and precursors become neutrophils instead of macrophagesM-CSF induces macropinocytosis by myeloid progenitors, which depends on WNK1Macropinocytosis enforces...
9.
Danielson L, Guijarro M, Menendez S, Higgins B, Sun Q, Mittal K, et al.
PLoS One
. 2023 Jan;
18(1):e0278844.
PMID: 36701370
Leiomyosarcoma (LMS) is an aggressive, often poorly differentiated cancer of the smooth muscle (SM) lineage for which the molecular drivers of transformation and progression are poorly understood. In microRNA (miRNA)...
10.
Aragon-Sanabria V, Aditya A, Zhang L, Chen F, Yoo B, Cao T, et al.
Clin Cancer Res
. 2022 May;
28(13):2938-2952.
PMID: 35499557
Purpose: Despite dramatic growth in the number of small-molecule drugs developed to treat solid tumors, durable therapeutic options to control primary central nervous system malignancies are relatively scarce. Chemotherapeutic agents...